article thumbnail

Recombinant DNA technology and its impact on drug discovery: Podcast

Drug Discovery World

Recombinant production is a field in which Sino Biological has extensive expertise – the company boasts several platforms to use recombinant DNA technology for the manufacturing of a variety of proteins and antibodies to expedite the process of novel drug identification and validation, for example. . Listen here.

article thumbnail

Recombinant DNA technology and its impact on modern drug discovery

Drug Discovery World

Recombinant production is a field in which Sino Biological has extensive expertise – the company boasts several platforms to use recombinant DNA technology for the manufacturing of a variety of proteins and antibodies to expedite the process of novel drug identification and validation, for example. .

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Exploring the Miracle Antibody Drug Conjugate Technologies

Roots Analysis

Conventional conjugation technologies used for the development of ADCs exploited the superficial lysine residues that were inherent to the native antibody structure, or the inter-chain cysteine residues, for drug-linker attachment.

article thumbnail

Beyond the Pill: The Rise of Biologics and the Evolution of Pharmaceutical Therapies

Cloudbyz

Understanding Biologics: Biologics are a class of therapeutic agents derived from living organisms, such as cells, tissues, or proteins. Unlike traditional small molecule drugs, which are chemically synthesized, biologics are produced through complex biotechnological processes, often involving recombinant DNA technology.

Gene 73
article thumbnail

Leading innovators in gene splicing using nucleases for the pharmaceutical industry

Pharmaceutical Technology

110 innovations will shape the pharmaceutical industry According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

article thumbnail

Sanofi/GSK restart COVID-19 vaccine trials after tweaking formulation

pharmaphorum

The vaccine is based around an adjuvanted recombinant protein, which will be tested in a new phase 2 study to assess the response including in older adults. Sanofi’s shot combines the recombinant DNA technology it uses to make flue vaccines with the adjuvants GSK uses to boost the immune system with its jabs.

article thumbnail

Can artificial intelligence help craft new medicines?

Drug Discovery World

The drug target for Penicillin is a protein that helps bacteria to synthesise its cell wall. One of the first and most basic requirements for a protein to be characterised as a drug target is to show that inhibiting its function prevents the disease. Salvarsan was soon overtaken by the Penicillin antibiotics.